Tariq Kewan, MD
Clinical FellowDownloadHi-Res Photo
About
Titles
Clinical Fellow
Biography
Tariq Kewan, M.D., is a hematology/oncology fellow at Yale University. He received his medical degree from Jordan University of Science and Technology and completed residency at Cleveland Clinic Foundation/Fairview Hospital. Dr. Kewan also pursued a one-year of post-doctoral Translational Hematology/BMT training at Cleveland Clinic where he worked under the mentorship of Professor Jaroslaw Maciejewski. Dr.Kewan is currently completing a master degree in Clinical Research at Ohio State University. His research focuses on understanding the pathophysiology and the molecular features of Myeloid Malignancies. In addition, he is interested in bone marrow failure diseases. Dr. Kewan is interested in an academic career with a focus on Malignant Hematology.
Departments & Organizations
Education & Training
- Translational Hematology/BMT
- Cleveland Clinic (2022)
- Residency
- Cleveland Clinic/Fairview Hospital (2021)
- MD
- Jordan University of Science and Technology (2015)
Board Certifications
Internal Medicine
- Certification Organization
- AB of Internal Medicine
Research
Research at a Glance
Publications Timeline
A big-picture view of Tariq Kewan's research output by year.
22Publications
Publications
2021
Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria.
Gurnari C, Pagliuca S, Kewan T, Bahaj W, Mori M, Patel BJ, Visconte V, Maciejewski JP. Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. Blood Cancer Journal 2021, 11: 187. PMID: 34839350, PMCID: PMC8627504, DOI: 10.1038/s41408-021-00582-5.Peer-Reviewed Original ResearchCharacteristics and outcomes of adverse events after COVID-19 vaccination.
Kewan T, Flores M, Mushtaq K, Alwakeel M, Burton R, Campbell J, Perry H, Al-Jaghbeer M, Abi Fadel F. Characteristics and outcomes of adverse events after COVID-19 vaccination. Journal Of The American College Of Emergency Physicians Open 2021, 2: e12565. PMID: 34693399, PMCID: PMC8514147, DOI: 10.1002/emp2.12565.Peer-Reviewed Original ResearchOutcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland clinic experience.
Kewan T, Gunaratne TN, Mushtaq K, Alayan D, Daw H, Haddad A. Outcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland clinic experience. Transfusion 2021, 61: 2014-2018. PMID: 33724474, PMCID: PMC8250532, DOI: 10.1111/trf.16368.Peer-Reviewed Original ResearchPrognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors.
Kewan T, Ko T, Flores M, Sallam Y, Haddad A, Daw H. Prognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors. European Journal Of Haematology 2021, 106: 682-688. PMID: 33565130, DOI: 10.1111/ejh.13598.Peer-Reviewed Original ResearchDirect Oral Anticoagulants Versus Warfarin and Enoxaparin in Ovarian Vein Thrombosis.
Covut F, Kewan T, Perez O, Thapa B, Babar A, Alomari M, Haddad A, Daw H. Direct Oral Anticoagulants Versus Warfarin and Enoxaparin in Ovarian Vein Thrombosis. American Journal Of Therapeutics 2021, 28: e260-e263. PMID: 31524638, DOI: 10.1097/MJT.0000000000001084.Peer-Reviewed Original Research
2020
Heparin-Induced Thrombocytopenia in a Patient With Coronavirus Disease-19: Diagnostic and Management Challenge.
Kewan T, Covut F, Daw H, Haddad A. Heparin-Induced Thrombocytopenia in a Patient With Coronavirus Disease-19: Diagnostic and Management Challenge. American Journal Of Therapeutics 2020, Publish Ahead of Print PMID: 33416245, DOI: 10.1097/MJT.0000000000001282.Peer-Reviewed Original ResearchTreatment of Acute Renal Vein Thrombosis With Direct Oral Anticoagulants: A Case Series.
Ahmed R, Covut F, Kewan T, Haddad A, Daw H. Treatment of Acute Renal Vein Thrombosis With Direct Oral Anticoagulants: A Case Series. American Journal Of Therapeutics 2020, Publish Ahead of Print PMID: 33416247, DOI: 10.1097/MJT.0000000000001258.Peer-Reviewed Original ResearchCOVID-19 patient with immune thrombocytopenic purpura.
Kewan T, Almhana F, Schwartzman L, Daw H, Haddad A. COVID-19 patient with immune thrombocytopenic purpura. International Journal Of Laboratory Hematology 2020, 42: e260-e262. PMID: 32786138, PMCID: PMC7436710, DOI: 10.1111/ijlh.13303.Peer-Reviewed Original ResearchClinically significant bleeding with immune checkpoint inhibitors: A retrospective cohort study.
Kewan T, Covut F, Ahmed R, Haddad A, Daw H. Clinically significant bleeding with immune checkpoint inhibitors: A retrospective cohort study. European Journal Of Cancer (Oxford, England : 1990) 2020, 137: 285-287. PMID: 32811686, DOI: 10.1016/j.ejca.2020.07.005.Peer-Reviewed Original ResearchLTA, LEP, and TNF-a Gene Polymorphisms are Associated with Susceptibility and Overall Survival of Diffuse Large B-Cell lymphoma in an Arab Population: A Case-Control Study.
Al-Khatib SM, Abdo N, Al-Eitan LN, Al-Mistarehi AW, Zahran DJ, Kewan TZ. LTA, LEP, and TNF-a Gene Polymorphisms are Associated with Susceptibility and Overall Survival of Diffuse Large B-Cell lymphoma in an Arab Population: A Case-Control Study. Asian Pacific Journal Of Cancer Prevention : APJCP 2020, 21: 2783-2791. PMID: 32986381, PMCID: PMC7779465, DOI: 10.31557/APJCP.2020.21.9.2783.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
honor The ASH Abstract Achievement Award
National AwardASHDetails10/01/2021United States